Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities

The emergence and continuous development of immune checkpoint inhibitors (ICIs) therapy brings a revolution in cancer therapy history, but the major hurdle associated with their usage is the concomitant ICIs-related toxicities that present a challenge for oncologists. The toxicities may involve non-...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Ya, Fu, Yang, Zhu, Bo, Wang, Jun, Zhang, Bicheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7572846/
https://www.ncbi.nlm.nih.gov/pubmed/33123120
http://dx.doi.org/10.3389/fimmu.2020.02023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7572846/
https://www.ncbi.nlm.nih.gov/pubmed/33123120
http://dx.doi.org/10.3389/fimmu.2020.02023

Ejemplares similares